Inflammation Determines the Pro-Adhesive Properties of High Extracellular D-Glucose in Human Endothelial Cells In Vitro and Rat Microvessels In Vivo by Azcutia, Verónica et al.
Inflammation Determines the Pro-Adhesive Properties of
High Extracellular D-Glucose in Human Endothelial Cells
In Vitro and Rat Microvessels In Vivo
Vero ´nica Azcutia
1, May Abu-Taha
2, Tania Romacho
1, Marta Va ´zquez-Bella
1, Nuria Matesanz
1, Francis W.
Luscinskas
3, Leocadio Rodrı ´guez-Man ˜as
4, Marı ´a Jesu ´s Sanz
2,5, Carlos F. Sa ´nchez-Ferrer
1, Concepcio ´n
Peiro ´
1*
1Departamento de Farmacologı ´a y Terape ´utica, Facultad de Medicina, Universidad Auto ´noma de Madrid, Madrid, Spain, 2Departamento de Farmacologı ´a, Facultad de
Medicina, Universidad de Valencia, Valencia, Spain, 3Center for Excellence in Vascular Biology, Department of Pathology, Brigham and Women’s Hospital and Harvard
Medical School, Boston, Massachusetts, United States of America, 4Servicio de Geriatrı ´a y Unidad de Investigacio ´n, Hospital Universitario de Getafe, Madrid, Spain,
5CibeRes CB06/06/0027 Carlos III Health Institute, Spanish Ministry of Health, Spain
Abstract
Background: Hyperglycemia is acknowledged as an independent risk factor for developing diabetes-associated
atherosclerosis. At present, most therapeutic approaches are targeted at a tight glycemic control in diabetic patients,
although this fails to prevent macrovascular complications of the disease. Indeed, it remains highly controversial whether or
not the mere elevation of extracellular D-glucose can directly promote vascular inflammation, which favors early pro-
atherosclerotic events.
Methods and Findings: In the present work, increasing extracellular D-glucose from 5.5 to 22 mmol/L was neither sufficient
to induce intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression, analyzed
by flow cytometry, nor to promote leukocyte adhesion to human umbilical vein endothelial cells (HUVEC) in vitro, measured
by flow chamber assays. Interestingly, the elevation of D-glucose levels potentiated ICAM-1 and VCAM-1 expression and
leukocyte adhesion induced by a pro-inflammatory stimulus, such as interleukin (IL)-1b (5 ng/mL). In HUVEC, high D-glucose
augmented the activation of extracellular signal-regulated kinase 1/2 (ERK 1/2) and nuclear transcription factor-kB (NF-kB)
elicited by IL-1b, measured by Western blot and electromobility shift assay (EMSA), respectively, but had no effect by itself.
Both ERK 1/2 and NF-kB were necessary for VCAM-1 expression, but not for ICAM-1 expression. In vivo, leukocyte trafficking
was evaluated in the rat mesenteric microcirculation by intravital microscopy. In accordance with the in vitro data, the acute
intraperitoneal injection of D-glucose increased leukocyte rolling flux, adhesion and migration, but only when IL-1b was co-
administered.
Conclusions: These results indicate that the elevation of extracellular D-glucose levels is not sufficient to promote vascular
inflammation, and they highlight the pivotal role of a pro-inflammatory environment in diabetes, as a critical factor
conditioning the early pro-atherosclerotic actions of hyperglycemia.
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Introduction
Vascular inflammation plays a pivotal role in the initiation and
progression of the atherosclerotic plaque [1]. Indeed, the
migration of circulating leukocytes from the blood to sites of
extravascular injury is an early pro-atherosclerotic event mediated
through a multistep adhesion cascade, initiated by the tethering of
leukocytes to the endothelium, followed by weak, transient
adhesive interactions manifested as leukocyte rolling, which leads
to firm leukocyte adhesion and ultimately to transmigration
through the vascular endothelium [2,3]. Cell adhesion molecules
(CAMs), including intercellular adhesion molecule-1 (ICAM-1)
and vascular adhesion molecule-1 (VCAM-1), which are expressed
by activated endothelial cells, play a crucial role in leukocyte
adhesion and migration [2,3].
Diabetes mellitus is characterized by a systemic pro-inflamma-
tory environment, exhibiting enhanced basal and postprandial
circulating levels of pro-inflammatory cytokines, including inter-
leukin (IL)-1b, IL-6 and tumor necrosis factor-a (TNF-a) [4,5]. An
over-expression of pro-inflammatory CAMs has been reported in
the cardiovascular system of animal models of diabetes [6,7].
Furthermore, diabetic patients exhibit enhanced circulating levels
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10091of soluble ICAM-1 and VCAM-1 [8–10], which are considered to
reflect vascular CAMs expression and represent prognostic
markers of macrovascular complications and cardiovascular
mortality [11].
Hyperglycemia, both basal and postprandial, has been identi-
fied over the years as an independent risk factor for cardiovascular
diseases [4,12,13]. Indeed, sera from diabetic patients increase in
vitro the adhesion of human monocytes and the expression of
CAMs in human endothelial cells [14,15]. It remains controver-
sial, however, whether or not high D-glucose itself can stimulate
such vascular pro-inflammatory mechanisms. Supporting a direct
role of high D-glucose, Morigi et al. [14] first described enhanced
VCAM-1 and ICAM-1 expression and leukocyte-endothelial
adhesive interactions after incubating endothelial cultures for
24 h with 30 mmol/L extracellular D-glucose. Other studies have
later on reported increased CAMs expression in human
endothelial cells exposed to high D-glucose concentrations during
time periods ranging from 24 h to 14 days [16–18], which has
been attributed, at least in some cases, to hyperosmolarity [16].
Contrarily, an earlier work by Kim et al. [19] neither found
induction of VCAM-1 and ICAM-1 nor enhanced adhesion of
HL60 leukocytes by high D-glucose (25 mmol/L for 7–10 days) in
human endothelial cells. More recently, Rasmussen et al. [15]
suggested that the in vitro induction of CAMs in human endothelial
cells by diabetic sera could not be solely attributed to high D-
glucose concentrations, but more likely to the presence of serum
cytokines. Additionally, both Cacicedo et al. [20] and Wada et al.
[21] have demonstrated that high D-glucose alone does not induce
the expression of genes encoding for VCAM-1 or ICAM-1 in
human endothelial cells.
At present, the therapeutical approaches for preventing
diabetes-associated cardiovascular diseases are mostly focused on
tightly controlling hyperglycemia. In fact, some clinical trials in the
90’s indicate that intensive blood-glucose control delays the onset
and slows the progression of microvascular disease, both in type 1
and type 2 diabetes, although macrovascular complications are
only prevented in a limited way after years of treatment [22–25].
Nevertheless, other recent trials with type 2 diabetic patients do
not even show a beneficial effect of intensive glycemic control on
the rate of cardiovascular events or deaths associated to
atherosclerotic macrovascular disease [26–28]. Therefore, it has
been now suggested that D-glucose is not the major mechanistic
pro-atherosclerotic mediator in diabetes [29].
To clarify this point, it is necessary to carefully dissect the direct
contribution of elevated D-glucose to the activation of early pro-
inflammatory vascular events that initiate the atherosclerotic
process. On the other hand, the potential interaction between D-
glucose and pro-inflammatory cytokines, as two co-existing
conditions in diabetes that may promote vascular inflammation,
is still largely unknown and should be addressed. For this purpose,
we have explored the respective contribution of both D-glucose at
high concentrations and the pro-inflammatory cytokine IL-1b to
endothelial CAMs expression and leukocyte trafficking, by
combining both in vitro and in vivo approaches.
Materials and Methods
Ethics statement
The investigation conforms with the principles outlined in the
Declaration of Helsinki. Experiments with human cells were
reviewed and approved by the ethics committee of Universidad
Auto ´noma de Madrid and Hospital Universitario de Getafe, and
written informed consent was obtained from all donors. The
investigation with animals conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85–23, revised 1996)
and was approved by the ethics committee of Universidad de
Valencia.
Materials
Culture plastic ware was from TPP (Tragadingen, Switzerland).
M199 and fetal calf serum were from Biological Industries (Beit-
Haemek, Israel). Human recombinant IL-1b was purchased from
Peprotech (London, UK), with an endotoxin level below 0.1 ng
per mg. D-glucose was supplied by Serva (Heidelberg, Germany).
Endothelial cell growth supplement, heparin, L-glucose, pyrrol-
idine dithiocarbamate, PD 98059 and, unless otherwise stated, all
other reagents were purchased from Sigma Chemical Co. (St.
Louis, MO).
Cell isolation and culture
Human umbilical vein endothelial cells (HUVEC) were
enzymatically isolated, as previously described [30], and cultured
in M199 medium supplemented with 20% fetal calf serum (FCS),
25 mg/mL endothelial cell growth supplement (ECGS), 100 mg/
mL heparin and antibiotics [30]. For experiments, HUVEC at
passages 1–5 were used.
For adhesion under flow assays, HL60 leukocytes were obtained
from American Type Culture Collection (ATCC; Rockville, MD)
and grown in RPMI-1640 medium (Biowhittaker, Walkersville,
MD) supplemented with 10% FCS and antibiotics.
Flow cytometry
Confluent HUVEC monolayers were treated with different
concentrations of D-glucose (5.5 and 22 mmol/L), either alone or
in combination with increasing concentrations of IL-1b. The non-
metabolizable analogue of D-glucose, L-glucose, was used as an
osmotic control. After 18 h, the expression of VCAM-1 and
ICAM-1 at the cell surface was measured by flow cytometry. In
brief, HUVEC were gently detached with phosphate-buffered
saline (PBS) containing 0.05% trypsin, fixed with 2% paraformal-
dehyde and blocked with PBS containing 3% bovine serum
albumin (BSA) for 15 min. Cells were then suspended in PBS
containing 0.5% BSA and incubated for 30 min with primary
antibodies against VCAM-1 (clone IE5) or ICAM-1 (clone 6.5B5;
Chemicon, Temecula, CA), both at a 1/100 dilution. Detection of
primary antibodies was performed using an appropriate Alexa
Fluor 488-secondary antibody (Molecular Probes-Invitrogen
Corporation, Carlsbad, CA; dilution 1/250). Fluorescence was
measured in a FACScan flow cytometer (Beckton-Dickinson,
Franklin Lakes, NJ), and data analyzed using Cell Quest software
(Beckton-Dickinson, Franklin Lakes, NJ).
The expression of CD11b/CD18 integrins was determined on
human leukocytes in heparinized whole blood. Blood samples
were obtained from buffy coats of four healthy donors by Ficoll
Hypaque density gradient centrifugation. Samples (basal glucose
concentration: 5.660.3 mmol/L) were incubated at 37uCw i t h
PBS or D-glucose (16.5 mmol/L to achieve a final concentration
of around 22 mmol/L), either alone or in combination with IL-
1b (5 ng/mL) for 18 h. Samples were then incubated for 20 min
on ice in the dark with saturating amounts (10 mL) of the
conjugated mAb anti-human-CD11b/CD18-FITC (clone ICRF
44; Serotec, Madrid, Spain). Red blood cells were lysed and
leukocytes fixed using an automated EPICS Q-PREP system
(Coulter Electronics, Hialeah, FL). Samples were run in an
EPICS XL-MCL flow cytometer (Beckman-Coulter, Hialeah, FL)
[31].
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ICAM-1, VCAM-1 and NF-kB were visualized in HUVEC by
indirect immunofluorescence, accordingly to a previously de-
scribed protocol [32]. Primary antibodies against VCAM-1
(dilution 1/250), ICAM-1 (dilution 1/25) or the NF-kB p65
subunit (dilution 1/100; Transduction Laboratories, Lexington,
KY) were used, followed by incubation for 1 h at room
temperature with an Alexa Fluor 488-conjugated secondary
antibody (1/250). Cell nuclei were counterstained with 49-6-
diamidino-2-phenylindole (DAPI; Molecular Probes-Invitrogen).
HUVEC were observed with an Eclipse TE300 epifluorescence
microscope (Nikon, Tokyo, Japan).
Nuclear extracts and electrophoretic mobility shift assay
HUVEC were exposed to the different treatments during 1, 4, 6
and 18 h and nuclear extracts were prepared as described before
[32]. A commercial oligonucleotide (Promega, Madison, WI)
encoding the NF-kB consensus sequence (59-AGTTGAGGG-
GACTTTCCCAGGC-39) was 59-end labeled using [c-
32P]ATP
and T4 polynucleotide kinase (Promega, Madison, WI) and
purified using MicroSpin
TM G-25 columns (GE Healthcare,
Chicago, IL). For binding reactions, nuclear extracts (5 mg) were
incubated on ice for 15 min in a reaction buffer [40 mmol/L
HEPES (pH 7.0), 140 mmol/L NaCl, 5 mmol/L dithiothreitol,
10 mg/mL BSA, 0.01% Nonidet P-40, 4% Ficoll and 0.05 mg/mL
poly(dI-dC).poly(dI-dC)]. After addition of the labeled oligonucle-
otide (,50,000 cpm) the reaction mix was further incubated for
20 min at room temperature. For competition experiments a 100-
fold excess of unlabeled doubled-stranded oligonucleotide was
added to the binding reaction. DNA-protein complexes were
resolved on 4% nondenaturing polyacrylamide gels in 0.5x TBE
(45 mmol/L Tris-borate, 1 mmol/L EDTA, pH 8.0) at 4uC. Gels
were dried and exposed to autoradiography at 280uC.
Western blotting
Extracellular signal-regulated kinase 1/2 (ERK1/2) activation
was determined by immunoblotting as previously described [32].
Polyclonal antibodies against both the phosphorylated (activated)
and total forms of ERK 1/2 (Cell Signaling Technology, Inc.,
Danvers, MA; dilution 1/1,000) were used, followed by incubation
with a horseradish peroxidase-conjugated secondary antibody
(dilution 1/10,000; Chemicon, Temecula, California, USA). ERK
1/2 activity was expressed as the phospho-ERK 1/2:total ERK1/
2 ratio.
Flow chamber assays
The in vitro adhesion of HL60 to HUVEC monolayers was
analyzed using a previously described live imaging flow model
[33]. Briefly, HUVEC monolayers grown on glass coverslips were
exposed for 18 h to 5.5 or 22 mmol/L D-glucose either alone or in
combination with IL-1b (5 ng/mL). Coverslips were placed in a
parallel plate flow chamber maintained at 37uC and HL60
leukocytes (1.5610
6 cells/mL) were drawn for 2 minutes across
the monolayers at a flow rate of 0.26 mL/min, corresponding to at
a shear stress of 0.5 dynes/cm
2. Monolayers were visualized with
an inverted microscope (Nikon TE2000, Nikon Inc., Melville,
NY), and at least 5 fields were recorded during 10 seconds each
using a phase contrast objective and VideoLab software (Ed
Marcus Lbs, Newton, MA).
Intravital microscopy
Non-diabetic male Sprague-Dawley rats (200–250 g) with a
basal glycemia of 4.960.1 mmol/L (results from 5 animals) were
employed. Animals were sedated with ether and intraperitoneally
injected with 10 mL of either PBS alone, PBS with D-glucose
(40 mg/kg), PBS with IL-1b (200 ng/kg), or PBS with D-glucose
plus IL-1b. Parallel experiments were performed replacing D-
glucose by L-glucose (40 mg/kg), which was used as an osmotic
control.
After 18 h, the mesentery was exposed in preparation for
intravital microscopy, following a previously described protocol
[31]. Single unbranched mesenteric venules (25–40 mmi n
diameter) were selected, and the diameters measured on-line
using a video caliper (Microcirculation Research Institute, Texas
A&M University, TX). The number of rolling, adherent, and
emigrated leukocytes was determined off-line during playback
analysis of videotaped images.
Immunohistochemistry
After the completion of the intravital microscopy measure-
ments, the mesentery was isolated, fixed in 4% paraformaldehyde,
dehydrated using graded acetone washes at 4uC, and embedded in
paraffin wax for localization of ICAM-1 and VCAM-1, using a
modified avidin and biotin immunoperoxidase technique as
described previously [31]. Anti-rat-VCAM-1 (clone 5F10, kindly
donated by Biogen Inc., Cambridge, MA) or anti-rat-ICAM-1
(clone 1A29, Serotec) monoclonal antibodies, or their isotype-
matched control murine antibodies (UPC 10, IgG2a and MOPC21
IgG1, Sigma Chemical Co.) were used. Positive staining was
defined as a venule displaying brown reaction product.
Statistical analysis
Results are expressed as mean6SEM from three to six
independent experiments. Student’s t-test was used for data points
and one-way ANOVA with Fisher’s post-test correction was used
for curves. A P value #0.05 was considered statistically significant.
Results
ICAM-1 and VCAM-1 expression on HUVEC
The mere elevation of extracellular D-glucose from 5.5 mmol/
L up to 22 mmol/L did not alter the basal expression of both
ICAM-1 and VCAM-1 in HUVEC after 18 h (107.0564.4 and
104.563.7% of the expression observed with 5.5 mmol/L D-
glucose, respectively. Figures 1C-1D). On the other hand, in
HUVEC incubated in a medium containing 5.5 mmol/L D-
glucose, the pro-inflammatory cytokine IL-1b enhanced the cell
surface expression of both ICAM-1 and VCAM-1 in a
concentration-dependent manner, with a sub-maximal effect
observed at 5 ng/mL (Figures 1A-1B).
Interestingly, the stimulating effect of IL-1b (5 ng/mL) on
ICAM-1 and VCAM-1 expression was potentiated when the
extracellular D-glucose concentration was switched from 5.5 up to
22 mmol/L (Figures 1C-1D). These findings were also visualized
by indirect immunofluorescence experiments, which confirmed
the synergism between 22 mmol/L D-glucose and IL-1b on
ICAM-1 and VCAM-1 expression, as well as the lack of effect of
high D-glucose by itself on endothelial cell activation (Figure 1E).
The interaction between high D-glucose and IL-1b was not
attributable to hyperosmolarity, since it was not reproduced after
replacing D-glucose by its non-metabolizable analogue L-glucose
(Figures 1C-1D).
To assess whether the potentiating effect of 22 mmol/L D-
glucose was restricted to IL-1b, we performed experiments in
which IL-1b was replaced by tumor necrosis factor (TNF)-a
(10 ng/mL). In HUVEC cultured in a 5.5 mmol/L D-glucose-
containing medium, TNF-a significantly induced both ICAM-1
Glucose and Leukocyte Adhesion
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non-stimulated HUVEC, respectively; P,0.05, results from four
independent experiments performed in triplicate). When the
glucose concentration was shifted up to 22 mmol/L, the
expression of both ICAM-1 and VCAM-1 was further significantly
enhanced to 1,364.526106.99% and 206.86614.45%, respec-
Figure 1. Effect of IL-1b and D-glucose on the expression of adhesion molecules in HUVEC. Cells incubated in a medium containing
5.5 mmol/L D-glucose were challenged for 18 h with IL-1b (0.1 to 10 ng/mL) and the levels of (A) ICAM-1 and (B) VCAM-1 were determined at the cell
surface by flow cytometry. In another set of experiments, cells were incubated for 18 h in medium containing 5.5 or 22 mmol/L D-glucose in the
presence or absence of IL-1b (5 ng/mL), after which (C) ICAM-1 and (D) VCAM-1 levels were quantified. L-glucose was used as an osmotic control.
*P,0.05 versus 5.5 mmol/L D-glucose without IL-1b; {P,0.05 versus 5.5 mmol/L D-glucose with IL-1b. (E) ICAM-1 (left panel) and VCAM-1 (right
panel) were visualized by indirect immunofluorescence in HUVEC cultured for 18 h in culture medium containing 5.5 or 22 mmol/L D-glucose in the
presence or absence of IL-1b (5 ng/mL). Nuclei were counterstained in blue with 49-6-diamidino-2-phenylindole (DAPI) (x400).
doi:10.1371/journal.pone.0010091.g001
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TNF-a in 5.5 mmol/L D-glucose; results from four independent
experiments performed in triplicate).
CD11b/CD18 expression on human leukocytes
In human leukocytes, the expression of CD11b/CD18 integrins,
involved in the leukocyte-endothelial interaction, was not
significantly modified after 18 h of incubation in 22 mmol/L D-
glucose (mean fluorescence intensity: 4.860.8 and 6.861.3
arbitrary units in 5.5 and 22 mmol/L D-glucose, respectively).
However, when the cells were exposed to IL-1b (5 ng/mL), a
marked induction of CD11b/CD18 was observed (mean fluores-
cence intensity: 13.063.2 arbitrary units, P,0.05 versus
5.5 mmol/L D-glucose), which was not further augmented in
the presence of 22 mmol/L D-glucose (mean fluorescence
intensity: 13.063.1 arbitrary units, P,0.05 versus 5.5 mmol/L
D-glucose).
ERK 1/2 and NF-kB activation in HUVEC and its role on
ICAM-1 and VCAM-1 expression
The incubation of HUVEC in 22 mmol/L D-glucose from 5 to
60 min did not result in increased ERK 1/2 activity, as compared
with cells incubated in 5.5 mmol/L D-glucose (Figure 2A).
Similarly, the exposure to high D-glucose did not result in NF-
kB activation from 1 to 18 h after stimulation (Figure 3A).
Conversely, IL-1b (5 ng/mL) in 5.5 mmol/L D-glucose activated
ERK 1/2 after 10–30 min stimulation (Figure 2A) and triggered
NF-kB binding activity from 1 to 6 h, returning to basal levels
after 18 h (Figure 3A). The respective ERK 1/2 and NF-kb
activation by IL-1b was further enhanced when the cytokine was
co-incubated with 22 mmol/L D-glucose (Figures 2A and 3A).
The translocation of NF-kB from the cytoplasm to the nucleus was
also visualized by immunofluorescence within the first hour of
incubation (Figure 3B). Again, just enhancing extracellular D-
glucose was not sufficient to promote NF-kB translocation,
although it potentiated the activation of NF-kB elicited by IL-1b
(Figure 3B).
To analyze the involvement of ERK 1/2 and NF-kB on ICAM-
1 and VCAM-1 expression, HUVEC were treated with IL-1b
(5 ng/mL), either alone or in the presence of the respective ERK
1/2 and NF-kB inhibitors PD 98059 (30 mmol/L) and PDTC
(100 mmol/L) for 18 h. Both inhibitors abolished the induction of
VCAM-1 elicited by IL-1b at any extracellular D-glucose
concentration (Figures 2B and 3C). In contrast, PDTC was not
able to modify the expression of ICAM-1 induced by IL-1b
(Figure 3C), while PD 98059 up-regulated the expression of this
CAM (Figure 2B).
In vitro HL60 leukocyte adhesion to HUVEC
We next performed in vitro assays under flow conditions to
investigate whether the synergism observed between high D-
glucose and IL-1b on CAMs expression was paralleled by
enhanced leukocyte adhesion to HUVEC monolayers. HL60
leukocyte adhesion was significantly enhanced when HUVEC
were stimulated with IL-1b (5 ng/mL) in 5.5 mmol/L D-glucose
medium for 18 h (Figure 4; Videos S1 and S3). This pro-adhesive
effect of the cytokine was further enhanced by 3.7-fold when
extracellular D-glucose was switched up to 22 mmol/L (Figure 4;
Video S4). High D-glucose alone did not promote leukocyte
adhesion to HUVEC (Figure 4; Video S2).
To assess whether the inhibition of either NF-kB or ERK 1/2
activation, which blocked VCAM-1 induction by IL-1b, could
prevent the adhesion of HL60 leukocytes to endothelial cells
adhesion, we performed additional experiments in which HUVEC
were pre-incubated with PDTC (100 mmol/L) or PD 98059
(30 mmol/L). PDTC did not significantly modify HL60 adhesion
induced by 5 ng/mL IL-1b (108.19619.39 and 90.7065.96% of
IL-1b alone in 5.5 mmol/L and 22 mmol/L D-glucose medium,
respectively; results from three independent experiments). For its
part, PD 98059 only partially inhibited HL60 adhesion promoted
by IL-1b (75.14610.11 and 60.6265.03% of IL-1b alone in
5.5 mmol/L and 22 mmol/L D-glucose medium, respectively;
P,0.05 vs matched IL-1b alone; results from three independent
experiments). In the absence of IL-1b, neither PD 98059 nor
PDTC did affect HL60 adhesion, independently of the D-glucose
concentration in the culture medium (data not shown).
In vivo leukocyte trafficking
In order to extend the functional data obtained in vitro to an in
vivo model, intravital microscopy was performed to examine
leukocyte trafficking in the mesenteric microvasculature of
Sprague-Dawley rats 18 h after the i.p. administration of a high
dose of D-glucose (40 mg/kg) in the presence or absence of IL-1b
(200 ng/kg).
When compared with control animals injected only with PBS,
IL-1b-treated rats showed a significant increase in venular
leukocyte rolling flux, adhesion, and emigration, as well as a
concomitant decrease in venular leukocyte rolling velocity
(Figures 5A-5D).
In those animals receiving only 40 mg/kg D-glucose, no
changes in the above-mentioned trafficking parameters were
observed (Figures 5A-5D). However, when IL-1b was co-injected
with D-glucose, a clear increase in leukocyte rolling flux, adhesion,
and migration was observed, as compared to IL-1b alone
(Figures 5A, 5C and 5D). This latter effect was not due to
hyperosmolarity, since L-glucose failed to mimic the potentiating
effect of D-glucose (Figures 5A-5D).
At the time of the experiments, no significant differences in
mean arterial blood pressure or venular shear rate were observed
among the different treatments performed (Table 1).
Immunohistochemical and histological studies
Immunohistochemical studies of the mesenteric tissue obtained
from PBS-treated animals revealed a weak staining for ICAM-1,
which was not modified in animals receiving only D-glucose
(Figure 5E). Additionally, no adhered or emigrated leukocytes
were observed in microvessels from PBS- or D-glucose-treated
animals (Figure 5E). IL-1b injection enhanced positive staining for
both CAMs, and leukocyte adhesion and transmigration through
the endothelial layer, especially in animals co-injected with D-
glucose (Figure 5E).
Discussion
The data presented herein do not support a role for high
extracellular D-glucose alone in promoting pro-inflammatory
endothelium-leukocyte interactions. In this context, just increasing
D-glucose concentration up to 22 mmol/L, which is twice the
plasma concentration considered to be indicative of diabetes after
the oral glucose tolerance test (11.1 mmol/L) [34], did not modify
CAMs expression or the adhesion of HL60 leukocytes to HUVEC
monolayers. Furthermore, the elevation of extracellular D-glucose
did not affect the expression of CD11b/CD18 integrins in
leukocytes, which are pivotal leukocyte molecules for adhesion
and migration [35]. Consistently, the increased monocytic
expression of adhesion receptors observed in type 2 diabetic
Glucose and Leukocyte Adhesion
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inflammation and only to a lesser extent with glycemic levels [5].
It is well established that pro-inflammatory cytokines are key
molecules in mediating leukocyte adhesion and transendothelial
migration [2]. Accordingly, we observed that IL-1b promoted
endothelial ICAM-1 and VCAM-1 expression, HL60 adhesion to
HUVEC monolayers, as well as the expression of CD11b/CD18
integrins on human leukocytes. Interestingly, although extracellu-
lar high D-glucose was not enough to induce the expression of
endothelial CAMs, it significantly enhanced the induction of
endothelial ICAM-1 and VCAM-1 elicited by IL-1b. Such a
potentiating effect of high D-glucose was not restricted to IL-1b,a s
Figure 2. ERK 1/2 activation and its impact on ICAM-1 and VCAM-1 levels in HUVEC. (A) Cells were incubated in medium containing
5.5 mmol/L or 22 mmol/L D-glucose with or without IL-1b (5 ng/mL) for 5–60 min, after which ERK 1/2 activation was determined by Western
blotting. Representative gels are shown on the top. (B) Involvement of ERK 1/2 in CAMs expression. HUVEC were cultured for 18 h in the above-
described conditions. PD 98059 (30 mmol/L) was used as an inhibitor of ERK 1/2 activation. *P,0.05 versus 5.5 mmol/L D-glucose; {P,0.05 versus
5.5 mmol/L D-glucose in the presence of IL-1b; {P,0.05 versus matched treatment without PD 98059.
doi:10.1371/journal.pone.0010091.g002
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whose levels are elevated in the circulation of diabetic patients and
whose release to the circulation is promoted by hyperglycemia [4].
The in vitro adhesion of HL60 leukocytes to endothelial cells
induced by IL-1b was also potentiated in a high D-glucose
environment. It can therefore be concluded that high D-glucose
on its own does not promote leukocyte-endothelial cell interac-
tions, but rather plays a modulatory role in such events by
enhancing an ongoing pro-inflammatory response on endothelial
cells. In agreement with these observations, we have recently
Figure 3. NF-kB activation in HUVEC and its impact on ICAM-1 and VCAM-1 levels. (A) HUVEC were incubated in medium containing
5.5 mmol/L or 22 mmol/L D-glucose in the presence or absence of IL-1b (5 ng/mL) during 1, 4, 6 and 18 h, after which NF-kB binding activity was
quantified by EMSA. Representative EMSAs are shown on the left. (B) Translocation of NF-kB from cytoplasm to nucleus was visualized by indirect
immunofluorescence in HUVEC cultured for 1 h as mentioned above (x1000). (C) Involvement of NF-kB in CAMs expression. HUVEC were cultured for
18 h in the above-mentioned conditions. PDTC (100 mmol/L) was used as NF-kB inhibitor. *P,0.05 versus 5.5 mmol/L D-glucose; {P,0.05 versus
5.5 mmol/L D-glucose with IL-1b; { P,0.05 versus matched treatment without PDTC.
doi:10.1371/journal.pone.0010091.g003
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for high D-glucose to inflame human vascular smooth muscle [36].
Additionally, the fact that high D-glucose did not potentiate
CD11b/CD18 integrins induction by IL-1b in human leukocytes
suggests that the synergism between high D-glucose and pro-
inflammatory cytokines may not affect every cell type involved in
leukocyte recruitment to the vascular wall, but rather more
specifically occurs in vascular cells.
We next aimed to gain insight into the cell signaling pathways
mediating the synergistic action between D-glucose and IL-1b in
human endothelial cells. Our data showed that just increasing the
extracellular D-glucose concentration did not activate ERK 1/2
nor NF-kB in HUVEC. While this observation contrasts with
previous reports showing ERK 1/2 and NF-kB activation in
HUVEC by high D-glucose [14,37], other studies have also failed
to detect the activation of both molecules in endothelial cells
exposed to elevated D-glucose levels [20,38,39]. We nevertheless
observed that high D-glucose potentiated the activation of both
ERK 1/2 and NF-kB elicited by IL-1b, indicating that the
elevation of extracellular D-glucose results in an over-activation of
endothelial signaling molecules triggered by a pro-inflammatory
stimulus. In this context, we have recently shown that, in cultured
human vascular smooth muscle cells, high D-glucose activates the
ERK 1/2 - NF-kB - inducible nitric oxide synthase axis, but only
when this signaling pathway is previously triggered by an
exogenous inflammatory stimulus [36]. In agreement with others
[40,41], we have further found in the present work that ERK 1/2
and NF-kB activation was responsible for endothelial VCAM-1,
Figure 4. Adhesion of HL60 leukocytes to HUVEC under flow conditions in vitro. HUVEC monolayers were exposed to either 5.5 or
22 mmol/L extracellular D-glucose in the presence or absence of IL-1b (5 ng/mL) for 18 h prior to leukocyte perfusion. *P,0.05 versus 5.5 mmol/L D-
glucose without IL-1b; {P,0.05 versus IL-1b in the presence of 5.5 mmol/L D-glucose. Representative micrographs showing HL60 adhesion to HUVEC
monolayers are shown on the top (x200).
doi:10.1371/journal.pone.0010091.g004
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PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10091Figure 5. In vivo leukocyte trafficking in rat mesenteric post-capillary venules. Animals were i.p. injected with 10 mL of PBS alone (C) or
supplemented with D-glucose (DG; 40 mg/kg), either in the absence or presence of IL-1b (200 ng/kg). L-glucose (LG; 40 mg/kg) was used as an
osmotic control. After 18 h, (A) leukocyte rolling flux, (B) leukocyte rolling velocity, (C) leukocyte adhesion and (D) leukocyte migration were
determined by intravital microscopy. *P,0.05 versus matched group without IL-1b; {P,0.05 versus IL-1b in PBS. Panel E shows representative
photomicrographs showing ICAM-1 and VCAM-1 immunolocalization and leukocyte adhesion and transmigration in post-capillary venules. The
brown reaction product indicates positive staining. Adhered and transmigrated leukocytes are marked with arrows in the right column. All panels are
lightly counterstained with hematoxylin (x400).
doi:10.1371/journal.pone.0010091.g005
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poly(ADP-ribose) polymerase-1 (PARP-1) [42] and AP-1 [43] have
been reported as promoters of ICAM-1 expression in different
vascular cell types, and might therefore be involved in the
induction of ICAM-1 by IL-1b observed herein and perhaps also
over-activated by high D-glucose. Blocking VCAM-1 expression
was not sufficient to totally prevent HL60 adhesion to endothelial
cells, neither under low or high D-glucose conditions. Indeed,
under NF-kB or ERK 1/2 blockade, the levels of ICAM-1
induced by IL-1b remained unchanged or even elevated, which
may still facilitate HL60 adhesion. In this context, it is worth
noting that the levels of lymphocyte function-associated antigen
(LFA)-1 integrin (the counterpart for endothelial ICAM-1) in
HL60 leukocytes are about 6-fold higher than those of very late
antigen (VLA)-4 (the counterpart for endothelial VCAM-1)
(unpublished observations).
The synergistic pro-inflammatory action between D-glucose
and inflammatory stimuli may in fact be on the basis of the highly
controversial reports existing on the ability of D-glucose per se to
trigger endothelial cell activation in vitro. We propose that a pro-
inflammatory response to high D-glucose can only occur when
cultured cells are already in an inflammatory state. As cells in
culture are in a rather artificial condition that facilitates
inflammation, they are therefore easily primed to respond to
abnormally high D-glucose. The degree of stress under which
cultured cells are when used for experimentation is variable, which
might explain the discrepancies encountered among the different
studies.
The enhanced acute release of pro-inflammatory cytokines
observed during postprandial hyperglycemia in diabetic patients
[4] has been related with a higher risk of suffering cardiovascular
events [4,13]. Studies in vitro using human endothelial cells have
also suggested that intermittent rather than constant high D-
glucose levels can be more effective in inducing the expression of
VCAM-1 and ICAM-1 [17]. By using intravital microscopy in the
rat mesenteric microvasculature, Booth et al. [44] analyzed the
effects of local acute intraperitoneal hyperglycemia on leukocyte-
endothelial cell interactions in vivo. These authors reported
increased leukocyte rolling and adherence after 12 h of intraper-
itoneal administration of moderate (20–25 mg/kg) and high (40–
45 mg/kg) doses of D-glucose, while no effect was observed with
the lowest dose (8–10 mg/kg) [44]. Herein, we have used a similar
in vivo model of local hyperglycemia to analyze the influence of a
high dose of D-glucose (40 mg/kg) on leukocyte trafficking after
18 h of its acute intraperitoneal injection. In accordance with our
in vitro findings, IL-1b significantly increased leukocyte rolling flux,
adhesion, and migration in vivo. More interestingly, D-glucose
markedly enhanced all these parameters, therefore favoring
vascular inflammation, but only when the cytokine was co-
injected. In fact, and in contrast with the observations of Booth
et al. [44], the mere administration of D-glucose in the absence of
the cytokine did not alter leukocyte trafficking parameters. These
functional data were accompanied by a parallel expression of both
CAMs in the mesenteric microvasculature.
Taken together these results, we propose that acute hypergly-
cemia per se is not sufficient to promote vascular inflammation.
More likely, the abnormally increased postprandial glucose
concentrations observed in the metabolic syndrome and type 2
diabetes [45] can only exaggerate the effects of an ongoing
inflammatory response. This may in fact constitute the main
mechanism by which postprandial hyperglycemia promotes
vascular inflammation and the development of diabetic vasculo-
pathy [4,13,46]. Even more, such a synergistic effect between high
D-glucose and inflammation could also explain why the expression
of CAMs and other inflammation-related molecules in response to
an infection is higher in hyperglycemic experimental models of
diabetes [47].
The results obtained in the present study using from in vitro to in
vivo approaches highlight that a pro-inflammatory pre-condition-
ing is necessary for extracellular high D-glucose to exert a
deleterious effect in the vasculature. A recent study in human
endothelial retinal cells suggests that cytokines, rather than high D-
glucose, are responsible for diabetes-related retinal endothelial
injury [38]. On the other hand, our data support the proposal that
D-glucose by itself is likely not a major mechanistic factor in the
development of diabetes-induced atherosclerosis [29] and they can
provide a possible explanation for the failure of intensive blood-
glucose control in preventing cardiovascular events associated to
type 2 diabetes [26–28].
Our findings further underpin the relevance of the chronic low-
grade pro-inflammatory environment observed in diabetes melli-
tus, as a pivotal factor conditioning the early pro-atherosclerotic
actions of elevated extracellular D-glucose levels. In fact, they are
in line with clinical observations in which a synergistic action of
hyperglycemia and inflammation seems to be critical in clinical
outcomes of acute coronary syndromes [48]. It is noteworthy that
the inflammatory environment that occurs in type 2 diabetes is a
rather complex phenomenon involving different cells and
mechanisms and not strictly related to hyperglycemia [45].
Therefore, treating only hyperglycemia may be not sufficient to
prevent and treat diabetic vasculopathy, and additional therapeu-
tical goals, such as lowering chronic inflammation, should be
carefully considered [49]. In this context, the subcutaneous
administration of the recombinant human interleukin-1-receptor
Table 1. Hemodynamic parameters of Sprague-Dawley rats used for intravital microscopy studies.
Treatment Mean arterial blood pressure (mm Hg) Shear rate in venules (s
21)
PBS 108.862.6 525.4642.7
D-glucose 112.663.9 493.9650.0
L-glucose 114.664.0 469.5650.4
IL-1b 113.464.6 502.8627.0
IL-1b + D-glucose 115.363.9 477.5666.9
IL-1b + L-glucose 108.865.5 500.8639.2
Parameters (mean 6 SEM) were measured 18 h after the i.p. injection of 10 mL of PBS alone (n=6), or containing D-glucose (40 mg/kg; n=5), L-glucose (40 mg/kg;
n=5), IL-1b (200 ng/kg; n=7), D-glucose plus IL-1b (n=6) or L-glucose plus IL-1b (n=5). No significant differences were found in mean arterial blood pressure or shear
rate in venules between any of the different treatments performed.
doi:10.1371/journal.pone.0010091.t001
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markers of systemic inflammation in type 2 diabetic patients [45].
In conclusion, the present work provides an experimental basis
to explain the failure of those therapeutic approaches directed only
to reduce hyperglycemia in preventing diabetes-associated athero-
sclerosis and calls attention on the necessity to reduce systemic
inflammation, either pharmacologically or through physical
exercise [50], in order to increase the benefit in preventing
cardiovascular events linked to type 2 diabetes or the metabolic
syndrome.
Supporting Information
Video S1 Confluent HUVEC monolayers were exposed to 5.5
mmol/L extracellular D-glucose for 18 h prior to leukocyte
perfusion (1.56106 cells/mL) drawn at 0.5 dynes/cm2 (x200).
Found at: doi:10.1371/journal.pone.0010091.s001 (2.77 MB
MOV)
Video S2 Confluent HUVEC monolayers were exposed to 22
mmol/L extracellular D-glucose for 18 h prior to leukocyte
perfusion (1.56106 cells/mL) drawn at 0.5 dynes/cm2 (x200).
Found at: doi:10.1371/journal.pone.0010091.s002 (2.76 MB
MOV)
Video S3 Confluent HUVEC monolayers were exposed to 5.5
mmol/L extracellular D-glucose in presence of IL-1b (5 ng/mL)
for 18 h prior to leukocyte perfusion (1.56106 cells/mL) drawn at
0.5 dynes/cm2 (x200).
Found at: doi:10.1371/journal.pone.0010091.s003 (2.66 MB
MOV)
Video S4 Confluent HUVEC monolayers were exposed to 22
mmol/L extracellular D-glucose in presence of IL-1b (5 ng/mL)
for 18 h prior to leukocyte perfusion (1.56106 cells/mL) drawn at
0.5 dynes/cm2 (x200).
Found at: doi:10.1371/journal.pone.0010091.s004 (2.61 MB
MOV)
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